COCH vs ABT

For growth investors, Envoy Medical, Inc.

(COCH) is the stronger pick with 7. 1% revenue growth year-over-year, versus 4. 6% for Abbott Laboratories (ABT). Abbott Laboratories (ABT) offers the better valuation at 11. 0x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Abbott Laboratories (ABT) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -20.

2%, compared to -93. 5% for Envoy Medical, Inc. (COCH). Over 10 years, the gap is even starker: ABT returned +166. 6% versus COCH's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

22β versus Envoy Medical, Inc. 's 0. 95β — meaning COCH is approximately 341% more volatile than ABT relative to the S&P 500.

By revenue growth (latest reported year), Envoy Medical, Inc.

(COCH) is pulling ahead at 7. 1% versus 4. 6% for Abbott Laboratories (ABT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to 17. 4% for Envoy Medical, Inc.. Over a 3-year CAGR, COCH leads at 0. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -98. 6% for Envoy Medical, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus -92. 4% for COCH. At the gross margin level — before operating expenses — ABT leads at 50. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

Envoy Medical, Inc. (COCH) offers the highest yield at 14. 7%, versus 2. 6% for Abbott Laboratories (ABT).

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 6% yield, +166. 6% 10Y return). Both have compounded well over 10 years (ABT: +166. 6%, COCH: -93. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COCH is a small-cap income-oriented stock; ABT is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.